Breaking News

Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer European Medicines Agency accepts marketing authorisation application for momelotinib for the treatment of myelofibrosis U.S. Small Business Administration Applications are Required before FEMA Individual Assistance can be Provided Apply for Assistance Even If You Are Unsure Department of Labor cites Dollar Tree again for endangering workers, continuing company’s lengthy history of workplace safety violations False Name Turns into Counterfeit U.S. Currency Discovery by Wellesley Island Border Patrol Agents Administrator Samantha Power Meets with Foreign Minister of Sri Lanka Ali Sabry | Readout FIS Challenges Nearly 200 Startups to Pitch their Boldest Ideas in First APAC Fintech Competition

Issued: London, UK – LSE announcement

GSK delivers 2012 core EPS of 112.7p and returns £6.3 billion to shareholders

  • Group sales -1%; flat excluding disposals of OTC brands
  • Successful R&D delivery: 6 new drugs filed since start of 2012
  • Phase III data expected on 14 assets in 2013 & 2014, including 9 new drugs/vaccines
  • Expansion of new major change programme across manufacturing, R&D & Europe; expected to deliver annual cost savings of at least £1bn by 2016
  • Strategic options to maximise efficiency and future performance in Europe under evaluation
  • In line with Consumer focus on core healthcare brands & emerging markets, initiating strategic review for Lucozade & Ribena
  • Continued focus on dividend growth; targeting share buy-backs of £1-2bn in 2013
  • Expect core EPS growth of 3-4% CER in 2013; sales growth of around 1% CER

View full Q4 2012 results (PDF)

More details with CEO & CFO interviews available in the quarterly results section of this website.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

GlaxoSmithKline Enquiries:

     

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

 

Sarah Spencer

+44 (0) 20 8047 5502

(London)

 

 

 

 

 

 

 

 

US Media enquiries:

Stephen Rea

+1 215 751 4394

(Philadelphia)

 

Mary Anne Rhyne

+1 919 483 0492

(North Carolina)

 

     

Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543

(London)

 

Lucy Budd

+44 (0) 20 8047 2248

(London)

 

Tom Curry

+ 1 215 751 5419

(Philadelphia)

 

Gary Davies

+ 44 (0) 20 8047 5503

(London)

 

James Dodwell

+ 44 (0) 20 8047 2406

(London)

 

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

 

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

 

 

 

 

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK’ s operations are described under ‘Risk factors’ in the ‘Financial review & risk’ section in the company’s Annual Report 2011 included as exhibit 15.2 to the company’s Annual Report on Form 20-F for 2011.

Source link